Navigation Links
Experts Propose New Criteria for Alzheimer's Diagnosis

An international group of experts have proposed new criteria for the diagnosis of Alzheimer's disease (AD), as they feel that the existing criteria are out of date due to unprecedented growth of scientific knowledge in the field.

"(These existing criteria) are the prevailing diagnostic standards in research; however, they have now fallen behind the unprecedented growth of scientific knowledge. Distinctive and reliable biomarkers of AD are now available through structural MRI, molecular neuroimaging with PET, and cerebrospinal fluid analyses," says Dr. Bruno Dubois, Salpetriere Hosptial, Paris, France.

According to experts, the new criteria for probable AD requires that patients show progressive memory loss over more than six months, and at least one or more of the supportive biomarker criteria-like atrophy in a particular part of the brain shown by MRI, abnormal biomarker proteins in the cerebrospinal fluid, a specific pattern on PET of the brain, and a genetic mutation for AD within the immediate family.

"These new criteria are centred on a clinical core of early and significant episodic memory impairment...the timeliness of these criteria is highlighted by the many drugs in development that are directed at changing pathogenesis," say the authors, whose proposal is put forward in a Position Paper published in The Lancet Neurology.

The researchers, however, admit that validation studies are required to advance the new criteria and optimise their sensitivity, specificity and accuracy.

"When effective disease-modifying medications are available, the argument for such biologically based studies will be even more compelling," conclude the authors.

"These proposed criteria move away from the traditional two-step approach of first identifying dementia according to degree of functional disability, and then specifying its cause. Rather, they aim to define the clinical, biochemical, struct
'"/>




Page: 1 2

Related medicine news :

1. Good carb, bad carb? Experts debate.
2. Spread Of Rocky Mountain Spotted Fever Is A Probability, Say Experts
3. Experts Recommend Preventive Measures For Avian Flu To Begin From Farms
4. Experts Insist That Neonatal Herpes Be Reported Regularly
5. Experts State Strategies To Increase Good Cholesterol
6. Cancer Can Recur Any Time, Experts Caution
7. Experts Building Bird Flu Warning System
8. Human Growth Hormone (HGH) - View of Experts
9. Experts urging artery screening in the UK
10. Genetic Experts of Hopkins Assists In Identifying Hurricane Katrina Victims
11. Birds Being Shot Owing To Bird Flu Fear: Wildlife Experts
Post Your Comments:
(Date:7/25/2008)...alif., July 25 /PRNewswire/ -- AutoGenomics, Inc. ...tatement on Form S-1 with the,Securities and Excha...blic,offering of shares of its common stock. The n... of which are expected to be offered by,AutoGenomi...ve not yet been,determined., J.P. Morgan Securiti...
(Date:7/25/2008)... The Retina Group of New York will prese...cular degeneration especially designed for seniors...ic Library at 116 Merritts Road, Farmingdale, NY 1...ndance is free and refreshments will be provided. ...-6100. , Hicksville and H...
(Date:7/25/2008)... Columbus-based law firm represents Pick...ef purchased at Columbus-area Kroger store , ...uly 25, 2008 -- http://www.donaheyohioinjurylawye... personal injury law firms in central Ohio, has fi... Court (Case No. 08CV9804) against The Kroger Co.,...
(Date:7/24/2008)...inn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (...port its 2008 second quarter and,year-to-date fina... quarter,and year-to-date financial results on Mon...ours., The company will host a conference call an...tern Time) on Tuesday, July 29, 2008. ev3,manageme...
Breaking Medicine News(10 mins):Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
...eatment given to people bitten by snakes or dogs. ...ission//. Africa, Latin America and Asia are the ...bite and scorpion stings. When it comes to snake b...wn as many of them prefer home remedies to hospita...
...sease. Yet recent studies have shown that the chan...es such as diet and exercise//, the chances of sur...rld Cancer Research Fund is putting around 50,000 ...ried out by Dundee University, Scotland. The thre...
In Search of Truth - 'Lie Detector
... women’s hospital in Vancouver, Canada last weeken...bies have a fair chance of survival//. Parents o...e infants and making them breathe on their own are...ctors now. Each of these babies weighed around 1...
Other Medicine News:Health News:In Search of Truth - 'Lie Detector 2Health News:In Search of Truth - 'Lie Detector 3Health News:In Search of Truth - 'Lie Detector 4
(Date:7/23/2008)...Body Have Greater Concentrations of,Stem Cells, A...wire/ -- Fat removed,from the lower abdomen and in...xcellent source of stem cells, with higher stem ce...ports a Brazilian-based study in August,s,Plastic ...l journal of the,American Society of Plastic Surge...
(Date:7/23/2008)...all/ -- Dendreon Corporation,(Nasdaq: DNDN ) toda...onitoring Committee (IDMC) to review in October 20...ng to the Company,s Phase 3 IMPACT (IMmunotherapy,...as D9902B) clinical trial,of PROVENGE(R) (sipuleuc...ctive cellular immunotherapy for the treatment of ...
(Date:7/22/2008)...swire-FirstCall/ -- Following a,thorough review th...harmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) to...hase 3 study in liver cancer. Progen confirmed,its...olio of compounds and,the company will actively se...es through Merger & Acquisition activity., The st...
(Date:7/22/2008)...- Nonin Medical, a leading innovator,of physiologi...as entered,the clinical testing phase with its bre...turation. Today,s most common application for this...gional blood oxygenation,in the brain -- cerebral ...n ongoing clinical study at the,Duke University Me...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Is Tap Water Safe for Your Dog 3F 20799 1Is Tap Water Safe for Your Dog 3F 20799 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 1Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 3Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 4Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 1Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 1IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 3IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 4IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 5
...wire/ -- Results from,the primary analysis of a ra...owed that 77 percent of treatment-experienced HIV-...600 mg tablets with,100 mg ritonavir (PREZISTA/r) ...(OBR) of antiretroviral (ARV) agents, reached a,pl...ared to 68,percent of patients taking Kaletra(R)1 ...
...ire-FirstCall/ --,Genzyme Corp. announced top-line... studies to assess the safety and efficacy of,tole...polymer,therapy for patients with Clostridium diff... 3 study of tolevamer liquid is fully,enrolled and...irst Phase 3 study known as the Polymer Alternativ...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 2Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 3Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 4
...eeds I-125 are brachytherapy sources which are imp...mors, especially in the prostate. The seeds remain...ic effect, i.e. after radioactive decay is complet...ey are supplied in a sterile form. Isoseeds I-125 ...
...mirrors for complete anterior chamber angle viewin...or easy handling and stability. Choice large or sm...llows static or dynamic gonioscopy without methylc... coating protects mirrors and is compatible with m...
Three mirrors of 64, 67 and 73 and a small diameter contact surface for use without methylcellulose. The fundus can be viewed through the central axis of the lens. Multi-layer polymer coating protect
West lacrimal cannula blunt tip with side port.
Medicine Products: